New combo therapy aims to boost colon cancer treatment before surgery
NCT ID NCT07468630
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding tolecizumab (a PCSK9 inhibitor) to standard chemoimmunotherapy can better shrink locally advanced colon cancer before surgery. About 106 adults with a specific type of colon cancer will receive either the combination or standard treatment alone. The main goal is to see if the cancer disappears completely in the surgical sample.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Daping Hospital Third Military Medical University, chongqing, chongqing 400000 Recruiting
RECRUITINGChongqing, Chongqing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can radiation plus immunotherapy make colon tumors disappear before surgery?
- Gut bacteria may shield nerves from chemo damage – a trial puts it to the test
- New drug combo aims to boost surgery success in colon cancer
- Blood test and AI team up to outsmart colon cancer recurrence
- Glow-in-the-Dark dye could help surgeons spot hidden cancer cells
- Blood test guides next move against stubborn colon cancer